Search Reports:

Enter company name or symbol or keyword from report title or report description. You can also use our advanced search option to further filter your results.

Accuracy of Opinions

977 (79%) - Correct
255 (21%) - Incorrect

Explanation

Recent News on Covered Stocks
Release of Phase III trial data of a small cap company's drug for opioid addiction expected in January - February 2012
Read Report  See Other Upcoming Events

Trading Ideas

Big Troubles for Biotech Big Pharma

Not just a Fat Issue

Read Report See More Reports>>
 
 

Commentary

Review the Top 10 Small Cap Biotech performers over the last month and their Drivers. This report lists the companies, their stock performance over the last month and some drivers that have contributed to the rise in the stock price. (April 7, 2010 through May 7, 2010)

Read Report

Biotech Stocks Performance Table – 2009: Lists over 250 Biotechnology companies and their stock performance for 2009 (Quarterly and Annually).

Read Report See More Reports>>

Upcoming Event Reports

NeurogesX, Inc. (NGSX) - Qutenza for Neuropathic Pain due to HIV-associated Peripheral Neuropathy/HIV-PN (FDA Panel)
Event Date - February 9, 2012 - PDF - Price: $20.00
Add to cart    View Report

Nektar Therapeutics (NKTR) - NKTR-102 for Second-line Ovarian Cancer (Phase II Detailed Data)
Event Date - March 2012 - PDF - Price: $20.00
Add to cart    View Report

Synta Pharmaceuticals Corp. (SNTA) - Ganetespib for Non-Small Cell Lung Cancer/NSCLC (Phase IIb/III GALAXY Trial)
Event Date - March 2012 - PDF - Price: $20.00
Add to cart    View Report

Immunogen Inc. (IMGN) - T-DM1 for HER2 Positive Second-line Metastatic Breast Cancer (Phase III trial data)
Event Date - March 2012 - PDF - Price: $20.00
Add to cart    View Report

Regeneron Pharmaceuticals, Inc. (REGN) - Zaltrap for Hormone-Refractory Prostate Cancer/HRPC (Final Phase III VENICE trial data)
Event Date - March 2012 - PDF - Price: $20.00
Add to cart    View Report

See More Reports>>
 

Performance of Upcoming Events
Year New BioMedicine * S & P 500 NASDAQ
2005 44.87% -0.11% 2.47%
2006 48.51% 14.89% 7.64%
2007 40.36% 6.34% 9.46%
2008 8.90% -33.84% -40.54%
2009 63.89% 23.49% 43.72%
2010 49.01% 12.64% 15.62%
*For the methodology of the performance calculation, please contact: kpaul@newbiomedicine.com See Other Performances

Event Calendars   See Description of Calendars

All Upcoming Events In Biotechnology - January 30, 2012
- Price: $80
Add to Cart

30 Upcoming Events Without Opinion - January 30, 2012
- Price: $10
Add to Cart

30 Upcoming Events With Opinion - January 30, 2012
- Price: $300
Add to Cart

New BioMedicine Top 10 Gainers - February 20, 2010
- Price: $10
Add to Cart

New BioMedicine Top 10 Losers - February 20, 2010
- Price: $10
Add to Cart

Click here to download Adobe Reader

Sample Report:

VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
 

Basket Reports:

Free Basket Reports

Specific theme-based reports at a value price
View Package

©Copyright 2012 New Bio Medicine, LLC. All Right Reserved.